Latest VentiRx Pharmaceuticals Inc. Stories
- Management Team, Funding, Immunotherapy Trials - SEATTLE, Sept.
Company also announces designation of Orphan Drug Status by FDA for VTX-2337 in Ovarian Cancer SEATTLE, April 17, 2014 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc.
Data Support Ongoing Randomized Phase 2 Study in Recurrent or Metastatic Head and Neck Cancer SEATTLE, Feb. 20, 2014 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc.
- Monstrous in size or character; huge; prodigious; monstrously perverse, savage, cruel, etc.